ArticleRespiratory medicine2019
Use of red cell distribution width in a population at high risk for pulmonary hypertension.
Article in Respiratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- The clinical characteristics and risk factors of pulmonary arterial hypertension in primary Sjögren disease: a single-center retrospective study.Clinical rheumatology · 2026Article
- The Level and Clinical Significance of Red Blood Cell Distribution Width in Patients With Congenital Heart Disease Associated With Pulmonary Hypertension.Pulmonary circulation · 2026Article
- Impact of red cell distribution width in school-age children with congenital heart disease.Heart and vessels · 2026Article
- Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH).Diagnostics (Basel, Switzerland) · 2025Article
- Development and validation of a mortality predictive model for ICU patients with primary pulmonary hypertension.Scientific reports · 2024Article
- Multimodal Screening for Pulmonary Arterial Hypertension in Systemic Scleroderma: Current Methods and Future Directions.Medicina (Kaunas, Lithuania) · 2024Review
- Analysis of hsa_circ_0136256 as a biomarker for fibrosis in systemic sclerosis.BMC biotechnology · 2024Article
- Immature reticulocyte fraction: A novel biomarker of hemodynamic severity in pulmonary arterial hypertension.Pulmonary circulation · 2024Article
- New Incremental Model for Predicting Mortality in Pre-Capillary Pulmonary Hypertension.Arquivos brasileiros de cardiologia · 2024Observational
- A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension.ERJ open research · 2022Review
- NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study.Respiratory research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPulmonary hypertension (PH) often presents with non-specific symptoms making early diagnosis difficult. Red cell distribution width (RDW) is a parameter routinely reported on an automated complete blood cell count that has been associated with numerous disease states. The purpose of this study was to further evaluate RDW as a biomarker for PH in at-risk populations.
methodsIn a retrospective, cross-sectional analysis of patients seen at a PH center over 1 year, we examined both patients with PH and patients at risk for but without PH (e.g. systemic sclerosis, [SSc]). We also studied a group of age-and sex-matched, non-diseased controls. Relevant characteristics were compared among the 3 groups using one-way ANOVA. Similar comparisons were made across World Health Organization (WHO) PH groups 1-4.
resultsRDW was highest in the PH patients (n = 181), intermediate in the at-risk for PH patients (n = 52), and lowest in matched controls (n = 100) (15.9 ± 2.8 vs 14.8 ± 2.8 vs 14.2 ± 1.1%, respectively; p < 0.0001). There were no significant differences in RDW across WHO PH groups (p = 0.50). SSc patients with PH had significantly higher RDW values compared to SSc patients without PH (16.0 ± 2.2 vs 14.4 ± 1.9%, respectively; p = 0.03).
conclusionsRDW is significantly higher in PH patients, without regard to disease etiology, when compared to age- and sex-matched non-diseased controls. Importantly, RDW is also higher in PH patients compared to at-risk patients, particularly in the SSc cohort. The ease of obtaining RDW as a biomarker may help detect incident PH at earlier stages among patients who are at high risk for development of PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.